FDA Grants Tentative Approval for Novitium's Generic Wakix, 'Pitolisant Hydrochloride' (ANDA 218495)
FDA Tentatively Approves Generic 'Pitolisant' for Wakix
The FDA has granted tentative approval for Pitolisant Hydrochloride tablets (ANDA 218495), a generic version of Wakix, a treatment for narcolepsy, submitted by Novitium Pharma, a subsidiary of ANI Pharmaceuticals. Tentative approval indicates that the drug meets the required technical standards for safety and efficacy but cannot be launched due to patent barriers. This decision allows Novitium to be ready to enter the market immediately upon the expiration or settlement of the original patent.
Wakix's Market Dominance and Mechanism in the Narcolepsy Market
The original Wakix is a key product of Harmony Biosciences. It is a histamine-3 (H3) receptor antagonist and inverse agonist that promotes histamine release in the brain, thereby inducing wakefulness. Unlike central nervous system stimulants, it is classified as a non-controlled substance with a low risk of abuse, giving it a competitive edge in the market. Wakix recorded net sales of approximately $868.5 million in 2025 and is expected to exceed $1 billion in 2026, making it a major product.
Patent Agreement and $15 Million Deal
Novitium challenged Wakix's patent, leading to a patent infringement lawsuit. However, the two companies settled the lawsuit through a strategic license agreement in January 2026. Harmony paid Novitium an upfront fee of $15 million and secured the right to use the patent, while also agreeing to collaborate on joint development. This agreement is seen as a win-win strategy that proactively resolves patent uncertainties and builds a future pipeline.
First Generic Launch Timeline and Outlook
Harmony has extended the exclusivity period by reaching agreements with several generic developers to delay the launch of generics until after 2030. Novitium's tentative approval is more significant in completing the regulatory procedures for securing a leading position in the first generic market after 2030, rather than having an immediate impact on sales. Investors should pay attention to both Harmony's ability to defend its patent exclusivity and ANI Pharmaceuticals' long-term generic sales potential.
This FDA tentative approval is a regulatory milestone that will determine the generic market structure for Wakix, a blockbuster narcolepsy treatment with $868.5 million in sales in 2025, after its U.S. patent expires. Harmony Biosciences has agreed with generic competitors such as Lupin to postpone the launch of generics until after 2030, which is expected to strongly maintain the original product's short-term sales defense. ANI Pharmaceuticals, which acquired Novitium Pharma, has eliminated litigation risk through a license agreement with an upfront fee of $15 million and secured the right to enter the market as the first generic in 2030. This will diversify the competitive landscape in the H3 receptor inverse agonist market and have a ripple effect of alleviating long-term healthcare financial burdens and expanding generic market share after the original drug's patent expires.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=ANDA218495